Taken together, these data indicate that SREBP-1 contributes to the anti-tumor response induced by BRAF inhibition and that SREBP-1 inhibition sensitizes therapy-resistant melanoma cells to MAPK-targeting therapy. Here, BRAF is linked to neoplasm.